Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Women and Children's Health Research Institute, Canada | OTHER |
Not provided
Not provided
Not provided
Not provided
Participants will be asked to wear a continuous glucose monitor for at least three days on three separate occasions. One testing session will be a no-exercise resting control session (90 minutes). One will be a moderate aerobic exercise session (30 minutes of exercise, 60 minutes of recovery), and the third will be a moderate weight-lifting session (~30 minutes of exercise, 60 minutes of recovery).The investigators will measure changes in blood glucose during exercise by drawing blood during and after exercise. Post-exercise glucose trends will be examined using continuous glucose monitoring.
Pre-test measures: Interested participants will be invited to either the Exercise Physiology laboratory the Augustana campus of the University of Alberta, or the Physical Activity and Diabetes Laboratory on the main campus of the University of Alberta. They will be asked questions related to menopause, PA levels, and medication. Blood pressure and heart rate will also be measured. Where participants are eligible, anthropometric characteristics will be measured using standard protocols. A blood sample will be drawn for assessment of HbA1c. Those who meet all eligibility criteria and complete informed consent forms will be asked to complete the initial exercise tests. Participants will perform a maximal aerobic capacity test with ECG monitoring, under the supervision of a certified exercise physiologist. Indirect calorimetry will be used to assess oxygen consumption and carbon dioxide production and will be used to extrapolate the participant's aerobic capacity. Participants will undergo a strength test for each of the ten exercises involved in the study, in order to estimate the their 1 repetition maximum. Participants will also be asked to undergo a dual energy x-ray absorptiometry (DXA) scan for body composition in the Clinical Research Unit at the Alberta Diabetes Institute. While this procedure generally requires proof of a negative pregnancy test, participants will be provided with a waiver in order to decline this test (in light of their menopausal status).
Testing sessions: Participants will be asked to arrive at the lab at around 4:00 pm for all three sessions, which will be randomly assigned. During the sessions, participants will be asked to perform one of the three activities: 1) seated rest 2) aerobic exercise (walking on a treadmill at 50% of the participant's pre-determined VO2max) or 3) resistance exercise consisting of 1 set of 10 repetitions of 10 different exercises with 90 seconds rest between sets. Blood samples will be drawn at baseline, after 10, 20 and 30 minutes of exercise, along with 30- and 60-minutes post-exercise via an IV catheter. Indirect calorimetry will be used to ensure that the participant is exercising at the appropriate intensity. Participants will be asked to match their daily food and insulin intake as closely as possible from one testing session to the next for the day before, day of and day after the testing session. The investigators will provide them with log sheets to assist in this task. They will also be asked to avoid strenuous exercise and alcohol intake.
A CGM sensor will be subcutaneously inserted by one of the investigators (trained by a group from the CGM manufacturer) into the anterior abdominal area of the participant, or on the back of the arm of the participant, approximately 2 days prior to the first testing session. The Dexcom G6 CGM receiver will store glucose data every 5 minutes for up to 10 days. The participant will be instructed on how to remove their sensor at least 24 hours after the exercise session, and will be asked to return the receiver to enable the upload of their data to Dexcom Clarity by the study team.
Interviews: During the third and final testing session, study participants will be invited to answer questions about their study participation experience, exercise preferences, barriers to exercise, and other information they feel may improve their exercise experience. These interviews will be audio recorded and transcribed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All participants | Experimental | All participants will take part in all three testing conditions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aerobic Exercise | Other | Walking at 60% of maximal aerobic capacity on a treadmill |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Blood glucose | Change in blood glucose | From 0 minutes to 45 minutes (beginning to the end of exercise/control) and then for 60 minutes after exercise |
| Measure | Description | Time Frame |
|---|---|---|
| mean continuous glucose monitoring (CGM) glucose | mean of all measurements over the selected time frames | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| coefficient of variation (CV) of CGM glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jane E Yardley, PhD | Contact | 780-679-1688 | jane.yardley@ualberta.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alberta Diabetes Institute | Recruiting | Edmonton | Alberta | T6G 2R3 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| D055070 | Resistance Training |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Resistance Exercise |
| Other |
Performing one set of 10 repetitions of 10 different weight-lifting exercises |
|
| No exercise | Other | Participants will rest in a supine position for 30 minutes. |
|
CV of CGM glucose over the selected time frames
| 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| standard deviation (SD) | SD of CGM glucose over the selected time frames | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| frequency of hypoglycemia | number of times that CGM glucose is equal to or less than 3.9 mmol/L | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| frequency of hyperglycemia | number of times that CGM glucose is equal to or greater than 10.0 mmol/L | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| percent time spent in hyperglycemia | percentage of time spent with CGM glucose equal to or greater than 10.0 mmol/L | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| percent time spent in hypoglycemia | percentage of time spent with CGM glucose equal to or lower than 3.9 mmol/L | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| percent time spent in range | percent of time spent with CGM glucose between 4.0 and 9.9 mmol/L | 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise |
| carbohydrate supplementation | grams of carbohydrate provided during exercise to prevent hypoglycemia | from 0 minutes to 45 minutes (during exercise) |
| Institut de recherches cliniques de Montréal | Recruiting | Montreal | Quebec | H2W 1R7 | Canada |
|
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D001519 | Behavior |
| D005081 | Exercise Therapy |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D064797 | Physical Conditioning, Human |